Oral heparin prevents neointimal hyperplasia after arterial injury: Inhibitory potential depends on type of vascular injury

Circulation

Volumn 104, Issue 25, 2001, Pages 3121-3124

  Welt, Frederick G P ^a,b,c   Woods, T Cooper ^d   Edelman, Elazer R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d Emisphere Technologies Inc   (United States)

Author keywords

Heparin; Restenosis; Stents

Indexed keywords

HEPARIN; OCTANOIC ACID DERIVATIVE; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; ILIAC ARTERY; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; STENT;

EID: 0035910111     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc5001.100837     Document Type: Article

References (25)

1. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
2. Inhibition of experimental neo-intimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration
3. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis
4. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations
5. Heparin absorption across the intestine: Effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers
6. 1 phase of the cell cycle
7. Suppression by heparin of smooth muscle cell proliferation in injured arteries
8. Kinetics of cell proliferation after arterial injury: I. Smooth muscle cell growth in the absence of endothelium
9. Kinetics of cellular proliferation after arterial injury: II. Inhibition of smooth muscle cell growth by heparin
10. Controlled release of heparin reduces neointimal hyperplasia in stented rabbit arteries: Ramifications for local therapy
11. Inhibition of rat arterial smooth muscle cell proliferation by heparin: In vivo studies with anticoagulant and nonanticoagulant heparin
12. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells
13. FGF binding and FGF receptor activation by synthetic heparin-derived di- and trisaccharides
14. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells
15. Effect of anticoagulants on delayed hypersensitivity reactions
16. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity
17. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity
18. Monocyte recruitment and neointimal hyperplasia in rabbits: Coupled inhibitory effects of heparin
19. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries
20. Low molecular weight heparin, reviparin, after PTCA: Results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study)
21. Low molecular weight heparin in prevention of restenosis after angioplasty
22. Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (the POLONIA study)
23. Orally administered heparin for preventing deep venous thrombosis
24. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis
25. Oral delivery of anticoagulant doses of heparin. A randomized, double- blind, controlled study in humans